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AM: atypical myopathy 
AM1 and AM2: horses 1 and 2 affected by atypical myopathy, respectively, used for the fatty acid analysis 
AMa and AMb: horse affected by atypical at day 3 and at day 10 after the onset of the clinical signs, used 
for the high resolution respirometry 
AMAG: atypical myopathy alert group 
ATP: adenosine triphosphate 
BHT: butylhydroxytoluene 
Bwt: body weight 
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C1, C2 and C3: control horses n°1, 2 and 3, respectively 
CHCl3: chloroform 
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D: doubtful case of atypical myopathy 
FID: flame ionisation detection 
ETF: electron-transferring flavoprotein 
ETF:QO: ETF:ubiquinone oxidoreductase 
ETS: electron transport system 
FAD: flavin adenine dinucleotide 
FADH2: Reduced form of flavin adenine dinucleotide 
FFA: free fatty acids 
FMN: flavin mononucleotide 
GBED: glycogen branching enzyme deficiency 
GLC: gas liquid chromatography 
GTP: guanosine triphosphate 
HAD: 3-hydroxyacyl-CoA dehydrogenase or β-hydroxyacyl-CoA dehydrogenase 
HP: case with a high probability diagnosis of atypical myopathy 
HRR: high resolution respirometry 
I: case infirmed for the diagnosis of atypical myopathy 
IV: intravenous 
LP: case with a low probability diagnosis of atypical myopathy 
MADD: Multiple Acetyl-CoA Dehydrogenase Deficiency 
NAD+: oxidized form of nicotinamide adenine dinucleotide 
NADH+H+: reduced form of nicotinamide adenine dinucleotide 
NADH-TR: NADH tetrazolium reductase  
NSAID: non steroidal anti-inflammatory drugs 
OXPHOS: oxidative phosphorylation 
PaO2: arterial partial pressures in O2 
PO: per os 
Q: coenzyme Q or ubiquinone 
SDH: succinate dehydrogenase 
TLC: thin layer chromatography 
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ETUDE EPIDEMIOLOGIQUE ET PHYSIOPATHOLOGIQUE DE LA MYOPATHIE 
ATYPIQUE DU CHEVAL AU PRE 
 
RESUME EN FRANCAIS 
Sur base des premiers cas belges, l’épidémiologie et la physiopathologie de la myopathie atypique ont été 
étudiées, mais son origine est toujours inconnue tandis que le mécanisme pathologique n’est qu’ébauché.  
Les objectifs de ce travail sont de préciser (1) l’épidémiologie, (2) les signes cliniques et (3) la 
physiopathologie de la myopathie atypique grâce à l’étude rétrospective des 165 cas européens recensés 
ces 2 dernières années.  Pour mieux définir sa physiopathologie, la composition en acides gras et la 
respiration de muscles prélevés sur chevaux atteints et contrôles ont été étudiées. 
Les nouveautés par rapport aux observations antérieures sont un taux de survie supérieur, l’atteinte d’ânes 
et de zèbres ainsi que la présence de signes cliniques peu ou/ pas rapportés antérieurement (e.g. 
hyperthermie, transit ralentis). Cette étude identifie certains facteurs pronostiques de survie (e.g. 
muqueuses normales, rester debout) et propose un traitement basé sur le dysfonctionnement observé 
(alimentation basée sur les sucres plutôt que les graisses).  En effet, l’étude de la respiration 
mitochondriale et de la composition en acides gras des muscles confirmait l’hypothèse d’un problème au 
niveau du métabolisme énergétique et lipidique (les muscles préférentiellement atteints par la myopathie 






MOTS-CLES EN FRANCAIS :  
Myopathie, cheval, épidémiologie, acides gras, respirométrie 
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EPIDEMIOLOGICAL AND PATHOPHYSIOLOGICAL STUDY OF ATYPICAL MYOPATHY 
IN GRAZING HORSES 
 
RESUME EN ANGLAIS 
The epidemiological study describes European cases affected by atypical myopathy from the autumn of 
2006 to the winter of 2008. Compared to previous studies, the described outbreaks were less devastating 
and for the first time clinically affected donkeys and zebras were reported. More horses were reported to 
present hyperthermia, penile prolapse and diminished digestive transit. Identified positive prognostic 
factors were normal mucosae and remaining standing. 
In the pathophysiological study, free fatty acids analysis and high resolution respirometry were performed 
on muscle samples of horse(s) affected with atypical myopathy and control horses. Muscles of affected 
horses contained more free fatty acids (especially palmitoleic acid (C16:1)) than controls. Muscles with 
the majority of type I fibers contained most free fatty acids. In the affected horse the mitochondrial 
respiration was severely diminished in all steps of the respirometry. As well the free fatty acid analysis as 
the high resolution respirometry demonstrated a severe problem in muscular energy metabolism. A 






MOTS-CLES EN ANGLAIS: 
Myopathy, horse, epidemiology, fatty acids, respirometry 
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INTRODUCTION 
Several recent studies have contributed to the understanding of the pathophysiological mechanism of 
atypical myopathy (AM) (Cassart et al., 2007; Westermann et al., 2008a; Westermann et al., 2008b). 
Nevertheless, the aetiology of AM remains unknown. Continuing epidemiological studies is of major 
importance to collect more information about AM in order to prevent the condition and handle affected 
cases in a better and more efficient way. Up to now, epidemiological studies have only been performed on 
Belgian cases confirmed by histology performed after post-mortem examination (Votion et al., 2007b; 
Votion et al., 2008).  Differences between countries could exist since the flora, pasture characteristics, and 
management of horses and pastures may differ. Epidemiological data for comparison of outbreaks within 
countries would be of value to narrow the common factors between affected areas.  This would be of help 
in our quest for the aetiological agent and strengthen our knowledge of identified risk and protective 
factors. Previously performed studies were not only geographically limited, but were also restricted to 
non-survivors confirmed on histology rather than including suspected cases based on clinical signs. In a 
first stage these studies were of great interest, excluding horses with clinical signs resembling AM but not 
affected by AM. However, by not including non-confirmed but highly suspected cases (including 
survivors) certain clinical information might have got lost. 
Recently, an overview of the recent knowledge about AM has been published (van Galen et al., 
2008c). After a summary of this review, the pathophysiology of AM will be discussed followed by a short 
review of the energetic metabolism of the muscle cell, preamble to introduce the objectives of our study. 
 
1. ATYPICAL MYOPATHY 
A syndrome of a highly fatal, acute myopathy affecting grazing horses was identified in 1983 and named 
“atypical myoglobinuria” (Anonymous, 1985). However, since myoglobinuria is only one of the possible 
clinical signs of the condition, the name atypical myopathy (AM) is now preferred (Votion et al., 2004). 
Atypical myopathy has been reported sporadically since the beginning of the 20th century in various parts 
of the world (Votion et al., 2004), but mainly in the UK. Since the new millennium it has been recognised 
in an increasing number of countries (Delguste et al., 2002; Gerber et al., 2006; van der Kolk, 2006; 
Palencia and Rivero, 2007), showing the emerging character of the condition. A similar condition has also 
been recognised in the United States of America (Finno et al., 2006). In Belgium and France, large 
outbreaks of AM are now encountered regularly (Puyalto-Moussu et al., 2004; Votion et al., 2007b). 
a. Epidemiology 
According to large clinical studies (Votion et al., 2007b; Votion et al., 2008), AM seems to occur in 
horses being on pasture for at least 1 week. The condition is reported to occur on bare, sloping pastures. 
Most of the pastures where AM declares contain humid areas and are crossed or being bordered by a 
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watercourse (Votion et al., 2007b; Votion et al., 2008). Affected horses are often young, unbroken and in 
poor to normal body condition, however older horses have also been affected (Brandt et al., 1997; 
Puyalto-Moussu et al., 2004; Votion et al., 2004; Votion et al., 2007b). The condition does not seem to be 
contagious, but is usually reported as outbreaks since particular environmental characteristics and specific 
weather conditions predispose to it. The climatic conditions favouring AM are little sunshine, cool 
temperature without heavy frost, heavy rainfall or humidity, and strong winds (Hosie et al., 1986; 
Whitwell et al., 1988; Votion et al., 2007b). These particular meteorological conditions could be the 
reason of the seasonal occurrence (i.e. the majority of cases are observed in autumn and some in spring 
and winter) (Votion et al., 2007b). 
b. Aetiology 
At this moment the aetiology of AM is still unknown, but several causes have been considered. Toxic 
products, like ionophores, herbicides, weed killers, nitrates and nitrites have been incriminated. However, 
testing for these products yielded negative results (Whitwell et al., 1988; Brandt et al., 1997). Phytotoxins 
have also been suspected, but plants known to be toxic for horses or other animals were not consistently 
present at the pastures of affected horses and/or were previously identified to cause other clinical signs 
than rhabdomyolysis (Hosie et al., 1986; Brandt et al., 1997; Puyalto-Moussu et al., 2004; Votion et al., 
2007b). No evidence of viral infections was found in cases with AM (Whitwell et al., 1988; Brandt et al., 
1997; Delguste et al., 2002). Mycotoxins could be involved as they are known to have potential toxic 
effects in equines (Osweiler, 2001). A described human fatal myopathic condition caused by mycotoxins 
supports this hypothesis (Bedry et al., 2001). Moreover, fungal growth and mycotoxin production depends 
on specific climatic conditions which are similar to those favouring AM. Several researchers have 
proposed clostridial toxins as a cause of AM (Delguste et al., 2002; Gerber et al., 2006). Unfortunately, 
until now no study was able to confirm neither mycotoxins, nor Clostridium spp. as the causative agent. 
Selenium or vitamin E deficiency can lead to a nutritional myopathy, resembling AM. Antioxidant status 
of AM cases was variable (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997), but nutritional 
myopathy is not thought to be the cause of AM since supplementation and treatment with selenium and 
vitamin E rarely improve the condition. However, these antioxidants may have a protective role against a 
potential oxidative stress encountered in AM. 
c. Pathogenesis 
The myodegenerative process of AM affects more selectively oxidative (i.e. the slow-twitch or type I 
fibers mainly found in postural and respiratory muscles) rather than glycolytic fibers (i.e. the fast-twitch or 
type II fibers predominantly found in locomotory muscles) (Brandt et al., 1997; Cassart et al., 2007; 
Palencia and Rivero, 2007). In addition, increased lipid storage is prominent in type I fibers (Cassart et al., 
2007). These observations alongside with no abnormal glycogen or polysaccharide accumulation 
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suggested an impaired oxidative metabolism and a preserved glycolytic pathway (Cassart et al., 2007). 
Moreover, a central role of the mitochondria in the pathogenesis of AM was suggested by the observation 
of mitochondrial ultrastructural changes (Cassart et al., 2007). 
Recently, these observations have been supported by the description of the biochemical defect 
occurring in AM (Westermann et al., 2007; Westermann et al., 2008b). A Multiple Acyl-CoA 
Dehydrogenase Deficiency (MADD) was found in confirmed cases. Dehydrogenase enzymes catalyse key 
events in fatty acids metabolism. They catalyse oxidation-reduction reactions using a coenzyme (i.e. flavin 
adenine dinucleotide; FAD) derived from the riboflavin (vitamin B2), thus suggesting that AM might 
result from a riboflavin deficiency or blockage. This MADD leads to dysfunction of the most efficient 
way for generating energy by the mitochondria, i.e. the oxidative phosphorylation (OXPHOS) from lipid 
substrates, therefore resulting in severe rhabdomyolysis, especially in postural and respiratory muscles. 
d. Clinical signs 
Clinical studies (Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b) report that affected 
horses show a sudden onset of severe general weakness and muscular stiffness and, often become 
recumbent within a few hours. They are sometimes even found dead on pasture without premonitory 
signs. Some are reluctant to move, others are so weak that they have difficulty keeping their head up (van 
Galen et al., 2008c). The affected horses show increased heart and respiratory rate, often hypothermia and 
congestive mucosae. Most cases keep a good appetite, although some suffer from esophageal obstruction 
(Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b). Dysuria with a 
distended bladder at rectal examination is frequently encountered. A lot of horses demonstrate signs of 
colic probably due to the bladder distension (Hosie et al., 1986; Brandt et al., 1997; Votion et al., 2007b), 
but rarely intestinal causes, as described by Sherlock and Mair (Sherlock and Mair, 2008) are found. The 
urine is dark-brown in the acute phase due to myoglobinuria (Hosie et al., 1986; Votion et al., 2004; 
Votion et al., 2007b). 
Subclinical cases have been described and can be horses grazing on the same premise as a 
clinically affected horse. They are often recognised when performing blood analyses on co-grazers of an 
affected horse, and they have a significant increase of serum activities of creatine kinase (CK) (Delguste et 
al., 2002; Votion et al., 2007b). They can evolve into clinical cases and so it is important to recognise and 
monitor them closely. It is thought that they are in balance with the causative agent, but a sudden 
imbalance may occur due to a trigger or a stress factor resulting in the clinical development of AM. These 
stress factors are suggested to be cold weather, exercise (Votion et al., 2003), transport (van Galen et al., 
2008c), or anaesthesia (Sherlock and Mair, 2008). 
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e. Diagnosis 
The clinical diagnosis of AM can be made based on history, clinical signs, blood and urine analysis, 
muscle biopsy and finally on post-mortem examination (Delguste et al., 2002; Cassart et al., 2007; Votion 
et al., 2007b; van Galen et al., 2008b). History is of major importance in the diagnosis. No cases are yet 
described not being out on pasture, probably because the etiologic agent is only found at pasture. 
Excluding other forms of rhabdomyolysis, for example exercise-induced myopathies, is paramount. 
However, as mentioned earlier, it is speculated that exercise as any other forms of stress can predispose 
for developing AM (Votion et al., 2003). The clinical signs are typical for any severe rhabdomyolysis, but 
not specific at all for AM. It is therefore difficult to make a diagnosis just based on clinical signs (van 
Galen et al., 2008b). At blood analysis muscle enzymes are massively increased, confirming the severe 
rhabdomyolysis (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2007b). Often 
hyperglycaemia and hyperlipaemia are present and liver enzymes are increased (Hosie et al., 1986; 
Whitwell et al., 1988; Votion et al., 2007b). A hypocalcaemia is almost always found, but no other 
important electrolyte disturbances are consistently reported. The urine is coloured due to the 
myoglobinuria, and should be differentiated from haematuria or haemoglobinuria (van Galen et al., 
2008b). 
The only way to make a definitive diagnosis of AM is by means of histology performed on a 
muscle samples. Biopsy is best performed on postural muscles in living horses or post-mortem on 
intercostal muscles (Cassart et al., 2007). At necropsy, discoloured muscles and myocardium, congestive 
lungs, petechiae and black-reddish gastro-enteric contents may be seen (Cassart et al., 2007). However, 
necropsy may also be disappointing with no specific observation. The most specific feature on histology is 
the important lipid accumulations in type I muscle fibers that undergo Zenker necrosis/degeneration 
(Cassart et al., 2007). 
f. Differential diagnosis 
Other severe myopathies described in the horse are sporadic or recurrent exercise-induced myopathies, 
glycogen branching enzyme deficiency (GBED), white muscle disease or nutritional myodegeneration, 
streptococcal myopathy and post-anaesthetic myopathy (van Galen et al., 2008b). Besides other severe 
myopathies, AM can be confounded with endotoxaemia, colic, neurological disorders (e.g. tetanus, 
botulism, rabies, meningitis, spinal cord disease), intoxications (e.g. ionophores, strychnine, carbamates, 
organophosphates, cassia occidentalis, acorn, white snakeroot), haematuria or haemoglobinuria of any 
cause (e.g cystitis, exercise-induced haematuria, urethral defects), or even lameness (e.g. iliac thrombosis, 
laminitis, polyarthritis, arthritis) (van Galen et al., 2008b). Worth mentioning is the fact that horses can 
develop increased muscle enzyme activity due to prolonged recumbency (Sherlock and Mair, 2008; van 
Galen et al., 2008b). 
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g. Treatment 
Since the aetiology of AM is not known, therapy of AM affected horses is mostly symptomatic and no 
treatment has been demonstrated to be efficient in horses with AM. One of the existing hypotheses about 
the aetiology includes Clostridial infections (Delguste et al., 2002; Gerber et al., 2006). Hypothetically, 
administration of metronidazole might therefore be helpful. Administration of botulism type C and D 
antiserum has also been proposed (Gerber et al., 2006). 
It is of great importance to administer fluid therapy to horses with an acute myopathy to avoid 
acute tubular necrosis due to myoglobinuria. Together with fluid therapy, electrolyte and acid-base 
balance should be maintained. Since AM cases seem prone to the development of hypocalcaemia, special 
attention should be carried out for calcium imbalances and administrating slow intravenous calcium 
borogluconate might be helpful. A lot of affected horses have difficulties urinating and should be relieved 
by regular or continuous bladder catheterization. When an indwelling catheter is placed or repeated 
catheterization is necessary, broad spectrum antibiotics should be administrated to prevent cystitis.  In 
general, horses fully regain their capacity to urinate once the myoglobinuria has disappeared (van Galen et 
al., 2008c). Although not all horses seem to suffer intensively (Votion et al., 2007), analgesia can be 
provided if necessary by non steroidal anti-inflammatory drugs (NSAID’s), morphine or morphine-
derivatives.  It should be noted that NSAID’s are a cause of renal toxicity, and especially with the 
presence of myoglobinuria caution is justified with their administration. Due to the progressively affected 
respiratory muscles a severe hypoxia can develop (Delguste et al., 2002; Votion et al., 2007b), and 
respiratory support in the form of nasal oxygen could be considered. For affected foals artificial 
ventilation might even be envisaged. Dantrolene sodium is proposed for limiting rhabdomyolyis in other 
myopathies (MacLeay, 2004; Nout and Reed, 2005). This drug limits the rate of calcium release from the 
sarcoplasmatic reticulum. Support for muscular function and repair should be offered by vitamins and 
anti-oxidants, like selenium, vitamin C and vitamin E. Muscle relaxants (i.e. acepromazine, alpha2-
agonists, methocarbamol, GGE, etc) can be used, but are rarely thought to be useful (van Galen et al., 
2008c). 
Once a horse is recumbent, regular turnings, good thick and clean bedding, and stimulating the 
horse to remain in sternal recumbency rather than in lateral recumbency can prevent further muscular and 
pulmonary compression as well as the development of important decubital ulcers (Nout and Reed, 2005). 
Affected horses should not be exposed to stress (for example exercise, transport), since it might aggravate 
their condition (Votion et al., 2003; Sherlock and Mair, 2008; van Galen et al., 2008c). 
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h. Prognosis 
The prognosis for most AM cases is not favourable. The mortality rate is estimated at 85% (Votion et al., 
2004) and most horses die within 3 days (Votion et al., 2007b). Prognostic factors recognised in clinical 
studies on fatal cases are normal respiration with normal arterial partial pressure of oxygen (PaO2) levels 
and the absence of permanent recumbency. Serum activities of CK have shown not to be of prognostic 
value (Votion et al., 2007b). 
It is important to inform the owner about the fact that his other horses are at risk to become 
affected, clinically or subclinically.  If possible, horses that are on the same pasture as an affected horse 
should be removed from this pasture and preferably placed in a box.  If not enough boxes are available for 
all, young horses should have priority since they are more at risk for AM (Votion et al., 2007b). Their 
level of CK activities should be checked during several days and they should be monitored closely for any 
annunciating signs. 
 
2. MUSCULAR METABOLISM 
To better understand the pathophysiology of atypical myopathy, it is necessary to review the pathways of 
energy metabolism of the skeletal muscle cell. 
a. Adenosine triphosphate 
The source of energy used for muscular contraction is adenosine triphosphate (ATP). The bond attaching 
the phosphate is a high-energy phosphate bond. When a phosphate is removed, this energy is released to 
be used for the contractile process. The amount of ATP present in muscles is only sufficient to sustain 
contraction for a couple of seconds. Therefore it is essential that new ATP is formed. This ATP can be 
formed by several pathways, being in chronological order the phosphocreatine-creatine system, the 
anaerobic glycogen-lactic acid system and the aerobic system (Guyton and Hall, 2006c, b; Votion et al., 
2007c; Lehninger et al., 1993g). 
b. Phosphocreatine-creatine system 
Phosphocreatine also contains a high-energy phosphate bond, like ATP, but a bigger amount of energy is 
released by the removal of the phosphate. Therefore it can easily provide enough energy to reconstitute the 
high-energy bond of ATP. This system also is only sufficient to sustain contraction for a couple of 
seconds (Lehninger et al., 1993g; Guyton and Hall, 2006c). 
c. The glycogen-lactic acid system 
Glycogen may provide a rapid energy source for either aerobic or anaerobic metabolism.  The glycogen 
stored in the sarcolemma can be split into glucose 6-phosphate (glycogenolysis), which can enter the 
glycolysis (catabolic pathway from glucose 6-phosphate). Glucose, obtained from the glycogenolysis or 
absorbed from the bloodstream, is split into pyruvate and energy is released to form 2 ATP molecules.  
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Two cytosolic reduced nicotinamide adenine dinucleotide (NADH) molecules are also produced during 
the glycolysis.  In the presence of oxygen, pyruvate is converted into acetyl-CoA and enters the Krebs 
cycle in the mitochondria. In absence of oxygen, pyruvate is converted to lactate in the cytoplasm, which 
diffuses out of the muscle cells into the interstitial fluid and blood. The ATP-production of this anaerobic 
system is a rapid energy source, but not an efficient compared to the aerobic system in terms of ATP 
yielded per mole of glucose (Lehninger et al., 1993b; Guyton and Hall, 2006b, c). 
d. The aerobic system 
i. General 
The aerobic system is the mitochondrial oxidation of glucose (and products of glycolysis), fatty acids and 
amino acids to provide energy (Figure 1).  These substrates are conversed into acetyl-CoA, and enter the 
Krebs cycle in which electrons are abstracted. These electrons are carried by NADH and reduced flavin 
adenine dinucleotide (FADH2).  Hydrogen is then oxidized by the electron transport system (ETS) of the 
OXPHOS (Figure 2).  In the overall reaction catalysed by the mitochondrial respiratory system, electrons 
move from NADH, succinate (via FADH2), or some other primary electron donors through Complex I, 
Complex II or coenzyme Q which is the junction to Complex III.  Electrons move from Complex III to 
cytochrome c and then to Complex IV which completes the sequence by transferring electrons from 
cytochrome c to O2 (thus consuming O2).  Electron flow through Complexes I, III and IV is accompanied 
by proton flow (H+) from the mitochondrial matrix to the intermembrane space. A last enzyme (the ATP 
synthase, sometimes called Complex V) catalyses the formation of ATP from ADP owing to the energy 
provided by the “proton-motive” force, i.e. the H+ flow back into the matrix through a pore associated to 
the ATP synthase (Figure 2).  During the Krebs cycle only a little amount of ATP is produced through the 
production of the high-energy compound guanosine triphosphate (GTP), but large amounts are produced 
during the OXPHOS (Lehninger et al., 1993a; Guyton and Hall, 2006b). 
ii. Fatty acids 
Since a problem in lipid metabolism is suspected in AM (Cassart et al., 2007; Westermann et al., 2007; 
Westermann et al., 2008b), and due to the importance of fatty acids for the aerobic metabolism in the 
skeletal muscle cell (MacLeay, 2004), the metabolism of fatty acids will be discussed more in detail. 
The first stage of using lipids for energy is the hydrolysis of triglycerides into free fatty acids 
(FFA) and glycerol, which will be released into the bloodstream to be taken to the muscle cell.  When 
glycerol enters the cell, it is immediately changed into glycerol-3-phosphate, entering the glycolytic 
pathway (Lehninger et al., 1993e; Guyton and Hall, 2006a).  The enzymes of fatty acids oxidation are 
located in the mitochondrial matrix.  Therefore, they must be transported into the mitochondria by the 
carnitine shuttle, which is a rate-limiting step (Lehninger et al., 1993e). The FFA with a chain length 
shorter than 12 carbons can however enter the mitochondria freely (Lehninger et al., 1993e). In the 
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mitochondria, the fatty acids undergo β oxidation: oxidative removal of 2-carbon segments in the form of 
acetyl-CoA (Lehninger et al., 1993e; Guyton and Hall, 2006a). This oxidation requires removal of 4 
hydrogen atoms (two pairs of electrons and four H+) per acetyl-CoA.  These electrons carried by FAD and 
NAD (i.e. FADH2 or NADH2) enter immediately the ETS of the OXPHOS. The acetyl-CoA molecules 
enter the Krebs cycle and later the OXPHOS as described above (Lehninger et al., 1993e) (Figure 3). 
The β oxidation of FFA occurs in four steps (Lehninger et al., 1993e; Guyton and Hall, 2006a). 
The first process is the dehydrogenation of fatty acyl-CoA with the production of a trans-fatty acid (a 
double bond), catalysed by acyl-CoA deshydrogenases.  The acyl-CoA deshydrogenases are flavoproteins, 
which use the coenzyme FAD derived from riboflavin (vitamin B2) (Lehninger et al., 1993e). The 
electrons removed from the fatty acyl-CoA are transferred to FAD. The produced FADH2 immediately 
donates its electron to an electron carrier of the ETS, the electron-transferring flavoprotein (ETF), from 
which they pass to coenzyme Q via ETF:ubiquinone oxidoreductase (ETF:QO) (Figure 4).  In the second 
step, water is added to the double bound to form β-hydroxyacyl-CoA. In the third step, β-hydroxyacyl-
CoA is dehydrogenated to form β-ketoacyl-CoA by the β-hydroxyacyl-CoA dehydrogenase (or 3- 
hydroxyacyl-CoA dehydrogenase; HAD). The liberated electrons are transferred to the oxidized form of 
nicotinamide adenine dinucleotide (NAD+) and are transported to Complex I of the ETS (Figure 4). In the 
fourth step, a thiolase catalyses the splitting of the β-ketoacyl-CoA into acetyl-CoA and a thioester.  The 
four steps are repeated to yield acetyl-CoA and ATP. The ATP production from fatty acids is much more 
important than that from glucose (131 ATP molecules per molecule of palmitoyl-CoA vs. 38 ATP 
molecules per glucose molecule) (Lehninger et al., 1993f). 
 
3. AIM OF RESEARCH 
Most of the knowledge about AM has been established on Belgian confirmed cases (Delguste et al., 2002; 
Votion et al., 2007b). Since the clinical expression of AM might be time and/or geographic dependent, the 
first part of this study aims at describing the clinical evolution and/or at better defining the clinical signs. 
This will be done through an epidemiological retrospective study of European cases recorded between the 
autumn of 2006 and the winter of 2008 and for the first time survivors of the condition will be desribed. 
The results of this first study might be of assistance for equine veterinarians concerning diagnosis, 
prognosis, treatment and prevention of AM. Due to the suspicion of a defect in mitochondrial lipid 
metabolism, the aim of the second part of this study is a search for the metabolic defect(s) associated to 
AM by interpreting preliminary results of a study with high resolution respirometry (HRR) applied on 
muscle micro-biopsy samples and by analysis of the FFA profile in affected muscles. 
Figure 1 - Aerobic metabolism (catabolism of proteins, fats, and carbohydrates in the three stages of 
cellular respiration)
 
Legend: Stage 1: oxidation of fatty acids, glucose, and some amino acids yields 
acetyl-CoA.  Stage 2: oxidation of acetyl groups in the Krebs (or citric acid) 
cycle includes four steps in which electrons are abstracted.  Stages 3: electrons 
carried by reduced nicotinamide adenine dinucleotide (NADH) and reduced 
flavine adenine dinucleotide (FADH2) are funnelled into a chain of 
mitochondrial electron carriers, providing the energy for ATP synthesis by 
oxidative phosphorylation. 
Picture from Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson 
and Cox. Worth Publishers New York, 2004, pp 602. 
 
 









Legend: Electrons from reduced nicotinamide adenine dinucleotide (NADH) and other oxidizable 
substrates pass through a chain of carriers arranged asymmetrically in the inner membrane of the 
mitochondria.  In this chemiosmotic model, electron flow is accompanied by proton transfer across the 
membrane, producing a chemical gradient (∆pH) and an electrical gradient (∆Ψ). The inner mitochondrial 
membrane is impermeable to protons; protons can re-enter the matrix only through proton specific 
channels (Fo).  The proton-motive force that drives protons back into the matrix provides the energy for 
ATP synthesis, catalyzed by the F1 complex associated with Fo. 
Picture from Principles of Biochemistry, fourth edition, Ed: Lehninger, Nelson and Cox. Worth Publishers 
New York, 2004, pp 705. 
 
 
Figure 3 - Lipid metabolism (stages of fatty acid oxidation) 
 
Legend: Stage 1 (β oxidation): a long chain fatty acid is oxidized 
to yield acetyl residues in the form of acetyl-CoA. Stage 2 (Krebs 
cycle): the acetyl groups are oxidised to CO2 via the Krebs (or 
citric acid) cycle.  Stage 3 (electron transfer chain): electrons 
derived from the oxidations of stages 1 and 2 pass to O2 via the 
mitochondrial respiratory chain, providing the energy for ATP 
synthesis by oxidative phosphorylation. 
Picture from Principles of Biochemistry, fourth edition, Ed: 








Figure 4 - The path of electrons to ubiquinone 
 
Legend: Electrons from nicotinamide adenine 
dinucleotide (NADH), glycerol 3-phosphate, succinate 
and fatty acyl-CoA converge to ubiquinone (coenzyme 
Q). 
Picture from Principles of Biochemistry, fourth edition, 
Ed: Lehninger, Nelson and Cox. Worth Publishers New 
York, 2004, pp 697. 
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MATERIALS AND METHODS 
1. EPIDEMIOLOGICAL STUDY 
a. Case selection 
Between the autumn of 2006 and the winter of 2008, an important amount of European cases suspected to 
suffer from AM were reported to the Faculty of Veterinary Medicine of Liege University in Belgium by 
the atypical myopathy alert group (AMAG) and by equine practitioners. These cases were allocated into 5 
categories: confirmed cases of AM (CC), cases with a high probability (HP) of being AM affected, cases 
with a low probability (LP) of being AM affected, cases infirmed for the diagnosis of AM (I), and cases 
with no possibility to conclude whether they suffered from AM due to a lack of clinical information (D for 
doubtful). 
Cases were defined as HP cases when they presented the following criteria: being out at pasture at 
the onset of clinical signs or at least within some days preceding, and overt signs of acute myopathy 
(diagnosed with an increased level of serum CK activity and/or myoglobinuria). Horses reported as being 
affected without any clinical information, but in the same period and at the same pasture as a previously 
defined HP or CC case were also considered to be HP cases.  Diagnosis of AM was confirmed (i.e. CC 
cases) when histology of post-mortem samples or muscle biopsies indicated a multifocal process 
compatible with Zenker degeneration and necrosis in fibers of postural muscles, respiratory muscles or 
both (Cassart et al., 2007). Cases were defined as I cases when histology of post-mortem samples or 
muscle biopsies did not reveal a diagnosis of AM. Cases were defined as LP cases when clinical signs 
typical for other conditions were present and/or when cases did not fulfil the criteria of the HP cases. 
Cases were defined as doubtful (D) when not enough clinical data and/or histological findings were 
present to confirm or infirm the suspicion of AM. Also information about co-grazers of reported cases was 
collected. 
With the data from these reported cases and their co-grazers a retrospective study was performed 
to precise the clinical and epidemiological description of AM, and to identify risk and protective factors 
for the development of AM and prognostic factors for survival. 
b. Collection of data 
Geographic, seasonal and demographic data, pasture characteristics, and management of the pastures and 
the involved cases were obtained from interviews of the owners by E-mail, telephone or by means of 
questionnaires obtained via the AMAG alert website (www.myopathieatypique.be). Clinical data were 
obtained from medical records obtained via AMAG alert website or from interviews with veterinarians. 
Climatic data were obtained from national climate websites of the different countries. 
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c. Statistical analysis 
From the defined categories, the following groups were considered for statistical analysis of the collected 
data: the HP/CC (that includes the data of the HP and CC cases), the LP/I (that includes the data of the LP 
and I cases), and the co-grazers groups. Seen the doubtful origin of the D cases they were excluded from 
statistical analysis. The HP/CC group was further subdivided into surviving and non-surviving cases. 
The mean of the quantitative parameters in each group with unequal variance was compared with 
a Welch’s test (Dagnelie, 1998). The risk factors calculated for different parameters were evaluated by 
mean of odds ratios as defined by Grenier (1990), which aimed at comparing the odds of exposure among 
groups.  If less than 50% of the questions of a certain parameter in a group was answered, this parameter 
was estimated not to be interpretable for statistical analysis. The limit of statistical significance of the 
conducted tests was defined as P < 0.05. 
 
2. FATTY ACID ANALYSIS 
a. Case selection 
Five horses were included in this part of the study. Two of these horses (AM1 and AM2) were diagnosed 
with AM based on history, clinical signs and presence of a multifocal process compatible with Zenker 
degeneration and necrosis in fibers of postural muscles, respiratory muscles or both on histology. Three 
other horses served as control horses (C1, C2 and C3), euthanized for other reasons and without any clinical 
evidence of a myopathy.  From all horses, muscle biopsies of different muscles were taken during general 
anaesthesia prior to euthanasia.  The sampled muscles were immediately frozen in liquid nitrogen and then 
kept at – 80°C until analysis. Due to delicate circumstances with assisting owners and because some 
horses dying before the end of sampling, not all muscles were sampled on every horse. The sampled 
muscles are shown in Table I. 
b. Lipid analysis 
In several steps, the amount of lipids, the amount of FFA and the profile of the FFA in the muscle samples 
were determined, as previously described in literature (Gorski et al., 1998; Nawrocki et al., 1999; 
Nawrocki and Gorski, 2004).  The first step was the extraction of the lipids from the muscle sample with 
chloroform.  The second step consisted of an analytical thin layer chromatography (TLC) to determine the 
total amount of FFA present in the samples. A second TLC (preparative TLC) was performed for isolation 
of those FFA, which were then methylated and used in a gas liquid chromatography (GLC) for 
determination of the profile of the FFA. 
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i. Extraction of the lipids 
The muscle biopsies were thawed, lyophilised and weighted.  They were then crushed in a phosphate 
buffer (0.15 M) in a fixed volume of 10 ml at a pH of 7.4.  The crushed samples were added to 8 ml of 
chloroform (CHCl3) (in a hermetic closed tube) while being stirred during 30 minutes.  The tube was then 
centrifuged at 2500 rotations per minute (power of centrifuge 1000 g) separating the aqueous phase of the 
lipid phase (lipids dissolved in chloroform).  The aqueous phase was aspirated and 6 ml of the chloroform 
phase (75%) were collected in a pre-weighted tube.  The solvent was evaporated under nitrogen flow and 
the possible traces of water were eliminated by lyophilisation.  Finally, the tube with its content was 
weighted, giving the weight of the extracted lipids.  This weight was used to calculate the weight of the 
total extracted lipids and finally to calculate the weight of lipids in mg per gram muscle. 
ii. Analytical thin layer chromatography 
The extracted lipids were replaced in solution by mixing them with 1 ml chloroform.  From this solution 
of total lipids, 10 µl were used to perform a TLC on a plate covered with silica gel (Merck© KGaA, 
Darmstadt, Germany) in a solvent mixture of petroleum ether, diethylic ether, acetic acid (70; 30; 2). Two 
control samples (20 µl) were used on every chromatography plate: one control sample contained a mix of 
triolein and cholesterol (S1), and the other control sample contained oleic acid and cholesteryl oleate (S2). 
This TLC permitted a separation of cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and 
phospholipids (in migrating order).  After migration, the plate was taken out of the chromatography tank 
and dried by air.  By vaporisation of a copper acetate solution on the plate followed by a heating of the 
plate at 180°C, the migrated lipids were visualised under the form of brown-black spots.  The percentage 
of every lipid class and their value in µg in the muscle sample and per gram of muscle was calculated by 
the use of densitometry. 
iii. Preparative thin layer chromatography and isolation of free fatty acids 
A second TLC, identical to the previous one, was performed on 15 µl of the lipid samples with the same 
control solutions and in the same conditions.  At the end of this TLC, only the S1 and S2 were visualised 
as described previously. The central part of the plate containing the samples was visualised only 
temporarily by vaporisation of iodine to be able to localise the FFA with precision. These locations were 
marked with a pencil. After evaporation of the iodine, the plate was vaporised with an antioxidant solution 
of butylhydroxytoluene (BHT) dissolved in CHCl3 preventing peroxidation of the lipids by exposure to 
oxygen. The zone corresponding with the localisation of the FFA was removed with chloroform by the 
Eluchrom (Camag©, Switzerland) at slow velocity (1 ml per 10 minutes).  The obtained solution of FFA 
was placed in a glass tube of 1 ml. 
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iv. Methylation and gas liquid chromatography 
The obtained solution of FFA was evaporated under a nitrogen flow and then methylated by 
diazomethane. After methylation, the solution was evaporated and the sample was replaced in solution 
with 10 µl of dichloromethane of which 0.5 µl were injected in the chromatograph. 
The following conditions of the GLC were used: Chromatograph Varian CX 3600 star, equipped 
with a capillary column Supelco SPTM-2380 (cyano-silicone) (30 meter; diameter 0.25 mm; thickness of 
the film 0.2 µm) and a flame ionisation detection (FID).  A nitrogen flow was used as gas vector (30 
ml/min) at 180°C during 6 minutes, followed by programmation of increase of the temperature 
(10°C/min) until 210°C.  Once this temperature was reached, it was maintained during 40 minutes. The 
gasses inducing the flame are air (300 ml/min) and hydrogen (30 ml/min). The column was standardised 
by a mix of methylated FFA (PUFA n°2 from Supelco; Bellefonte, PA, USA) and by individual 
methylated FFA (purchased from Sigma; methylated by diazomethane). The registration of the 
chromatogram was performed by an integrator.  The column separates the FFA based on the number of 
the carbons and based on the number of the double bonds in the FFA. 
The peaks were identified by comparing their retention time with the retention time of the FFA 
used as reference (PUFA n°2 or the individual FFA).  After localizing and identifying the peaks, the total 
surface of all peaks was calculated being equal to 100%. Thereafter the surface of each individual peak 
was calculated in percentage and converted into the amount of that specific FFA in µg/g muscle. 
c. Comparison 
A comparison concerning the lipid analysis was made between the horses affected with AM and the 
control horses. The different muscles were also compared to determine a specific localisation of the FFA, 




3. HIGH RESOLUTION RESPIROMETRY 
a. Case selection  
One horse affected with AM was available for micro-biopsy.  This horse was sampled at 3 days (AMa) 
and at 10 days (AMb) after the first clinical signs occurred. As control horses, three healthy resting horses 
were sampled. None of the three had a history or clinical signs suggestive for myopathy. 
b. Samples 
Biopsies were performed in vivo under local anaesthesia in the M. triceps brachii in order to sample cells 
with functioning mitochondria enabling to perform HRR.  The biopsy site was shaved and aseptically 
prepared using polyvidone iode soap (iso-Betadine® Savon Germicide, Meda Pharma, Belgium), alcohol 
and polyvidone iode solution (iso-Betadine® Dermique, Meda Pharma, Belgium).  Mepivacaïne 
hydrochloride 2% (Scandicaïne® 2%, AstraZeneca, Belgium) was locally injected at the site of biopsy.  
The skin was incised using a number 11 blade. A 14G biopsy needle (PRO-MAG™ Ultra, Inter.V®, US) 
was entered 5 cm deep into the muscle and with the use of a biopsy pistol (PRO-MAG™ Ultra, Inter.V®, 
US) a muscle micro-biopsy was sampled. This procedure was repeated 4-5 times in the same muscle using 
the same skin incision. The samples were immediately placed in a specific relaxing and biopsy 
preservation solution named “BIOPS” (Letellier et al., 1992) and were then used for HRR as previously 
described in literature (Wenchich et al., 2003; Votion et al., 2007a).  
c.  High resolution respirometry 
The oxygraph (Oxygraph-2k®, Oroboros, Austria) measures the oxygen (O2) use of living mitochondria 
(the mitochondrial respiration) of samples added in two glass chambers by means of two polarographic O2 
sensors.  A scientific software for HRR (DatLab 4, Oroboros, Austria) displays on-line the O2 flux (in 
pmol/(s*mg)) and the O2 concentration (in nmol/ml) over time.  Muscle fibers obtained by micro-biopsy 
were prepared according to the procedure of Lemieux and collaborators (2007) (Lemieux et al., 2007).  
Mitochondrial respiration of the muscle micro-biopsies was followed at 37°C in a medium called “Miro5” 
(Gnaiger et al., 2000) according to the titration protocol described by Votion and collaborators (2007) and 
summarised in Table II and Figure 5-7. 
d. Comparison 
Considering the fact that in the AM affected category only one horse was sampled, no statistical analysis 
was performed on this part of the study. 

























































































































AM1  x  x x  x  x x 
AM2 x x x x x x x    
C1  x  x x x     
C2   x   x x     
C3 x x    x  x   
Legend: AM = atypical myopathy affected horses; C = control horses. 
 
Table II - Multiple substrate-uncoupler-inhibitor titration protocol used for respiratory studies of equine 
permeabilized muscle fibers 
Step Added substrate Respiratory state Comments 
GM Glutamate + Malate Coupled leak state 
Respiratory resting state with 
substrates for Complex I, but no 
ADP 
GM-D ADP Coupled OXPHOS capacity with Complex I substrates 
Respiratory capacity in the active 
coupled state 
GM-Dc Cytochrome c --- 
Further addition of cytochrome c 
yields a test for integrity of the outer 
mitochondrial membrane (loss of 
cytochrome c would induce a 
stimulation of respiration) 
GMS-Dc Succinate Coupled OXPHOS capacity with Complex I+II substrates 
Respiratory stimulation by 
convergent electron flow from 
Complexes I+II at the Q-junction, in 
the coupled state 
GMS-UC FCCP ETS capacity with Complex I+II substrates 
Uncoupling by FCCP titration as a 
test for limitation of OXPHOS 
relative to ETS capacity 
S/Rot Rotenone ETS capacity with Complex II substrate 
ETS capacity with succinate, after 
blocking Complex I with rotenone 
AA Antimycin A Non-mitochondrial respiration of the permeabilized tissue 
Addition of Antimycin A (inhibitor 
of Complex III) 
 
Legend: ADP: adenosine diphosphate; OXPHOS: oxidative phosphorylation; FCCP: Carbonyl cyanide p-
(trifluoromethoxy) phenylhydrazone; ETS: electron transport system. 
Figure 5 - Glutamate + Malate as substrates for the high resolution respirometry 
 
Legend: Glutamate and malate activate dehydrogenase with reduction of nicotinamide adenine 
dinucleotide (NADH) in the Krebs cycle then feeding electrons into Complex I of the electron transport 
system (ETS).  However, no succinate is produced (because of a malate antiport which depletes 
metabolites for succinate production) and thus there is no reduced flavine adenine dinucleotide (FADH2) 
to feed Complex II of the ETS. 
Picture from: www.oroboros.at 
 
 
Figure 6 - Glutamate + Malate + Succinate as substrates for the high resolution respirometry 
 
Legend: Convergent electron flow to the Q-junction (see also Figure 7) with glutamate + malate + 
succinate combination.  The reduced nicotinamide adenine dinucleotide (NADH) and reduced flavine 
adenine dinucleotide (FADH2) produced in the Krebs cycle feed the electron transport system with 
electrons at the level of Complex I and II, respectively. 
Picture from: www.oroboros.at 
Figure 7 - The electron transport system 
 
Legend: Convergent electron transport at the levels of the Q-junction [Complexes I+II, glycerol 3-
phosphate dehydrogenase (GpDH) and electron-transferring flavoprotein (ETF)] and at the level of the 
reduced nicotinamide adenine dinucleotide (NADH) pool. PDH: pyruvate dehydrogenase (DH); MDH: 
malate DH; IDH: isocitrate DH; ODH: oxoglutarate DH; SDH, succinate DH; GDH: glutamate DH. 
Picture from: www.oroboros.at 
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RESULTS 
1. EPIDEMIOLOGICAL STUDY 
a. Division of the cases in the different categories 
Between the autumn of 2006 and the winter of 2008, a total of 165 European cases were reported, and 
information about 65 co-grazers was collected.  Figure 8a and 8b show the division of the reported cases 
in the different categories. Ninety-three cases (56%) were confirmed AM cases or cases highly suspected 
to suffer from AM (the HP/CC group). 
b. Geographic and seasonal distribution 
The geographic and seasonal distribution of the cases are shown in Figure 9, 10a and 10b. Most reported 
cases originated from Belgium and France.  Most of the Belgian reported cases were from the southern 
part of the country (provinces of Hainaut, Liege and Luxembourg). The province Walloon Brabant was 
considered as protective factor for the development of AM. No difference in provinces was noted between 
survivors and non-survivors. Most cases occurred during the autumn of 2006. 
c. Outcome and survival rate 
The outcome and the survival rates of the different groups are shown in Figure 11a-11b and Table III. 
None of the horses of the HP/CC group were found dead before showing any clinical signs. During the 
autumn of 2006, a higher survival rate was noted in France (57%) compared to the rest of the study period 
and other countries. The HP/CC cases were significantly more often euthanized and died less often of a 
natural death or were less often found dead compared to the LP/I cases. 
d. The horses 
i. Demographic data 
The age, sex, race and body condition of the reported cases are shown in Table IV and Figure 12. The 
HP/CC cases were often young ponies or saddle horses with a normal body condition, however older 
horses were also reported to be affected. Four donkeys (2 D and 2 HP cases), three zebra’s (1 CC and 2 
HP cases) and a deer (LP case) were present in the study population. No predisposition concerning age, 
race or body condition was present for the development of AM, however stallions were more and mares 
less at risk.  Sex, age and race had no influence on the outcome, but obese horses were less at risk to die 
from the condition. 
ii. Activity of the cases: work and pasturing 
The activity of the reported cases is shown in Table V. Only a minority of the reported cases was worked 
and none of the HP/CC cases was worked more than twice a week. All horses were affected while at 
pasture, except for 2 horses of the HP/CC group that had been stabled 2 days before the onset of their 
clinical signs and 3 horses of the LP/I group that had been stabled 10 days before. When the condition 
occurred, the majority of the horses spent 24 hours per day at pasture.  The period that the reported horses 
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grazed on the specific pasture ranged from 10 days to several years. Not being at pasture and being 
worked were protective factors, whilst being 24H/24H at pasture during winter was a risk factor for the 
development of AM. Being worked, being at pasture 24H/24H when AM occurred and the time that the 
horses had spent on the specific pasture had no influence on the outcome. 
iii. Medical history 
The medical history of the reported cases is shown in Table VI. Four reported cases had been diagnosed 
with a myopathy previous to the diagnosis or suspicion of AM; one D case and one LP/I case had suffered 
from an exercise-induced myopathy, and one LP/I case and one HP/CC case had suffered from a 
myopathy of unknown origin. Only a minority of the reported cases had travelled to other countries. The 
majority of the reported cases had been regularly dewormed and vaccinated. No significant differences 
regarding these parameters were noted between the groups. 
iv. Nutrition 
The nutritional status (complemented or not) of the reported cases is shown in Table VII. None of the 
reported cases had received food destined for other species. At the time of AM occurring, only about half 
of the HP/CC horses and their co-grazers were complemented, mostly with hay and concentrates. 
Complementing horses during the period in which AM occurred was a protective factor for the 
development of AM.  
e. The pastures 
A description of the pasture characteristics and management is given in Table VIII. Pastures of HP/CC 
cases were often sloping, non-treated, natural pastures containing trees, dead leaves, dead wood, humid 
zones and a water stream. Often, water from the distribution network was used and was drunk from a tank. 
The occurrence of previous deaths in horses (regardless the cause of death) on the pasture, and the 
presence of trees, dead leaves, and humid zones on the pastures were demonstrated to be risk factors for 
the development of AM. Dead wood was more often present on the pastures of survivors than of non-
survivors. 
f. Climatic conditions 
The climatic conditions during the period that AM occurred are described in Table IX. Often a change in 
temperature, wind and rain was marked by the owners when their horses became affected by AM. No 
heavy frost occurred in the 10 days before the first clinical signs were noted. Less rainfall in the 10 days 
preceding AM was considered a risk factor for the development of AM. No statistical differences were 
noted between survivors and non-survivors. 
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g. Clinical data 
i. Duration of the condition 
For the non-survivors, the duration of the clinical signs ranged from 0 to 10 days (mean ± SD: 1.2 ± 1.6 
days). The survivors fully recovered after 2 to 30 days (mean ± SD: 11.1 ± 6.7 days) and showed none to 
very few muscle atrophy. 
ii. Clinical signs 
Information about the clinical signs in the reported cases is given in Table X. Some owners noticed an 
abnormal behaviour before the onset of the clinical signs, described as depression and abnormal quietness. 
One horse refused to eat and another one fell over. The presence of an abnormal behaviour was not 
different between the studied groups. 
Affected horses were often presented with congestive mucosae, tachycardia, tachypnoea, 
dyspnoea and moderate suffering. As well normal rectal temperature as hypo- and hyperthermia have been 
encountered in HP/CC cases. Myoglobinuria was almost always noted in HP/CC cases and depression, 
weakness, stiffness, recumbency, and trembling were frequently reported clinical signs. In HP/CC cases, 
quite regularly other abnormalities than a distended bladder were encountered at rectal examination 
indicating a diminished digestive transit: dry and/or mucus covered faeces, impaction of the large colon. 
Some males showed a paraphymosis. The HP/CC cases showed significantly more frequently stiffness 
than the LP/I cases. The other clinical signs were not significantly different between those two groups or 
not interpretable. Survivors showed more often normal mucosae, less recumbency and remained more 
standing compared to non-survivors.  
iii. Creatine kinase activity 
The serum activity of CK in the reported horses is described in Table XI. The values in horses of the 
HP/CC group were always greater than 1000 IU/L. When the CK activity was measured repeatedly, the 
first value was always the lowest. In some cases, the presence of a myopathy could even be questioned 
based on these first samples, whereas a second sample 1 or 2 days later always demonstrated clearly a 
severe myopathic process. The probability of AM was significantly higher in cases with a serum activity 
of CK higher than 15000 IU/L and significantly lower in the cases with a serum activity of CK lower than 
1000 IU/L. No significant difference was noted between serum activity of CK of survivors and non-
survivors, although a tendency for a higher CK activity in survivors was revealed. 
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iv. Therapy 
The treatment, administered to the reported cases, is shown in Table XII.  The majority of the reported 
cases had received treatment, consisting mostly of fluid therapy, non-steroidal anti-inflammatory drugs 
and vitamins. The HP/CC cases were more often treated than the LP/I cases. All survivors had been 
treated, but no significant difference between survivors and non-survivors was noted. No significant 
differences in the used medication were noted between the studied groups. 
v. Diagnosis 
About one third of the reported cases had been autopsied to confirm or infirm the suspicion of AM 
(52/119) or had been diagnosed by muscle biopsy (12/165) (Table III). 
 
Figure 8a & 8b - Distribution of the reported cases of atypical myopathy reported in the present study (n 
= 165) and their co-grazers (n = 65) as a function of the probability of the diagnosis 
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Legend: CC = AM confirmed cases; HP = cases with a high probability of AM; LP = cases with a low 
probability of AM; I = infirmed cases of AM; D = doubtful cases of AM; Co-G = co-grazer. 
 
Figure 9 - The geographic distribution of the reported cases over Belgium 
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Legend: CC = AM confirmed cases; HP = cases with a high probability of AM; LP = cases with a low 
probability of AM; I = infirmed cases of AM; D = doubtful cases of AM. 
Figure 10a – Geographic and seasonal distribution of the reported cases over Europe 






























Figure 10b – Geographic and seasonal distribution of the confirmed cases or the cases with a high 
probability of being affected with atypical myopathy over Europe 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. FATTY ACID ANALYSIS 
a. Extraction of the lipids 
No difference between AM affected horses and control horses was present concerning the weight of the 
total lipids in mg/g muscle (Table XIII and Figure 13). 
b. Analytical thin layer chromatography 
The muscle samples of the control horses often had shown none or just traces of FFA at the TLC.  These 
FFA were then considered to be < 10 µg or < 0.5% of the measured weight of the total muscular lipids in 
order to be able to perform the calculations for the GLC. 
In all muscles of the AM affected horses the FFA were clearly visible at the TLC, in contrast to 
the control horses.  The muscles of the control horses that showed FFA at the TLC were the M. masseter 
(C3) and the M. brachiocephalicus (C1 and C3; see Figure 14a and 14b).  Differences in the other lipid 
classes were also visible (no quantitative data shown): in the affected horses less triglycerides were visible 
at the TLC than in the control horses and in some muscles of affected horses monoglycerides were 
identified.  In none of the horses, cholesterylesters were present. 
The mean muscular FFA in affected horses was higher than that of the control horses (Figure 15). 
The muscles with the highest FFA values were the M. masseter (in as well control horses as in AM 
affected horses), the Mm. intercostales (only sampled in AM affected horses) and the cardiac muscles 
(only sampled in AM1), however compared to the control horses the M. masseter had the lowest increase 
in FFA in affected horses (Figure 16 and Table XIV). 
c. Gas liquid chromatography 
It was not possible to identify all peaks of the GLC.  In all horses, small peaks with a very long retention 
time (longer than C20:5n3 or C24:2 or C22:4n6) were present, which were not identified due to their 
absence in the reference FFA (Figure 17). 
The profiles of the chromatograms were about the same in all horses. Some FFA were only 
present in 1 horse: C1 was the only horse with C24:2, while it had no C12:0 and no C14:1.  The FFA 
C22:4n6 only was present in the M. quadriceps of C2; C22:0 was only present in AM1; C22:1 was only 
present in some muscles of AM2 and C2.  Other FFA were present in all horses except one: C20:5n3 was 
not present in AM1; C22:1 was not encountered in C3. All these FFA, which were not present in all horses, 
were only present in small amounts. 
In percentage, the FFA also showed a quite similar division, except for C16:1 which was clearly 
present in a higher percentage in both affected horses compared to the controls, and C16:0 which was 
present in a higher percentage in the controls compared to the AM affected horses (Figure 18). In every 
muscle of the affected horses, the highest value of the FFA was obtained for C16:1 (20.9% - 42.1% and 
225.57 - 1435.7 µg/g muscle; mean 733.36 µg/g muscle) with the exception of the M. triceps of AM2 (a 
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long chain unidentified FFA; the next highest was C14:0). The FFA with the highest value in the control 
horses was as follows: C1 had as highest FFA in the 4 muscles C16:1, C10:0, and twice a very short chain 
unidentified FFA (< C10:0); C2 in all 3 muscles C16:0 (24.1% - 43.85% and 43.37 - 90.05 µg/g muscle; 
mean 72.48 µg/g muscle); and C3 in all 4 muscles C16:0 (14.77% - 40.42% and 42.12 - 1328.05 µg/g 
muscle; mean 479.31 µg/g muscle [but the M. masseter increases the mean substantially]). The peak of the 
C16:0 in the control horses expressed in µg/g muscle was much lower than the peak of C16:1 in the 
affected horses. 
The amount of the FFA was almost always higher in the AM affected muscles than in the control 
muscles, although differences were not that clear in all FFA as in C16:0 and C16:1 (Figure 19).  The 
exceptions consisted mostly of short and medium chains FFA (C10:0, C12:0, C14:1 and C16:0) in single 
muscles, and in C1 some long FFA (C20:5n3 and C24:2). These exceptions were often not visible in the 
charts with mean values. 
The FFA can be divided in saturated, mono-unsaturated and poly-unsaturated FFA dependant on 
the presence of and the number of double bonds. Control horses had a majority of saturated FFA. In 
general, affected horses had more of all three groups FFA compared to control horses, but they had a 
majority of mono-unsaturated FFA. 
Table XV shows the values of the identified FFA.  The identified FFA were 34.7% to 79.82% of 
the total FFA, with a mean of 53.8% for the AM cases and 56.9% for the controls. 
 
Table XIII - Weight of the total lipids and of the free fatty acids (FFA) in the sampled muscles of the 


















Atypical myopathy affected horses 
AM1 M.brachiocephalicus 
M. longissimus dorsi 
M. quadriceps femoris 
Mm. intercostales 
Interventricular septum of the myocardium 




















± 1 977 
AM2 M. masseter 
M. brachiocephalicus 
M. triceps brachii 
M. longissimus dorsi 

























± 1 318 
Control horses 
C1 M. brachiocephalicus 
M. longissimus dorsi 











    146.85* 
     109.05* 
     189.30* 
474 
± 653 
C2 M. brachiocephalicus 








     179.70* 
     205.35* 
     200.40* 
159 
± 13.6 
C3 M. masseter 
M. brachiocephalicus 
M. semi-tendinosis 









  3 877.79 
  1 616.59 
    285.15* 
    337.05* 
1 529 
± 1682 
Legend: (*) FFA not present or only in traces visible on the TLC, so < 10 µg or < 0.5 % of the weight of 
the measured total lipids.  To be able to perform the calculations for the GLC, the quantity of those FFA 
was arbitrary chosen to be 0.5% of the weight of the measured total lipids. 























































































Legend: A chromatography plate with 5 samples (9E-9K) of a control horse and 2 control 
samples (S1 and S2). The migration of the lipids occurs from ventral to dorsal and the TLC 
permits a separation of cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and 
phospholipids. After migration, the migrated lipids were visualised under the form of brown-
black spots. 







Legend: A chromatography plate with 5 samples (3B-3H) of an affected horse and 2 control 
samples (S1 and S2). The migration of the lipids occurs from ventral to dorsal and the TLC permits 
a separation of cholesteryl esters, triglycerides, FFA, cholesterol, monoglycerides and 
phospholipids. After migration, the migrated lipids were visualised under the form of brown-black 
spots. 








































































































e) AM1 AM2 C1 C2 C3
 
Legend : FFA = free fatty acids ; AM1 = case 1 affected with atypical myopathy ; AM2 = case 2 affected 
with atypical myopathy ; C1 = control horse 1; C2 = control horse 2; C3 = control horse 3 
 
Table XIV – Free fatty acids (in µg/g muscle) in specific muscles 




















   3 877.79 3 877.79  4 671.38 4 671.38  1.20 1.20 
M. 
brachiocephalicus 1 454.31 179.70 1 616.59 1 083.53 2673.79 2 515.43 2 594.61 2.47 2.32 2.39 
M. triceps brachii 
      2 367.70 2 367.70    
M. longissimus dorsi 
  146.85   146.85   848.75 2 472.86 1 660.81 5.78 16.84 11.31 
M. quadriceps 
femoris  109.05 205.35  157.20 1 627.20 1 898.16 1 762.68 10.35 12.07 11.21 
M. sacrocaudalis 
dorsalis    337.05 337.05       
M. semitendinosis 













   
Ventriclar free wall 





   
Legend: Grey = no corresponding samples between affected horses and controls; AM1 = case 1 affected 
with atypical myopathy ; AM2 = case 2 affected with atypical myopathy ; C1 = control horse 1; C2 = 
control horse 2; C3 = control horse 3 




































































































































































































































































































































































































































































































































Identified FFA  
Mean value for masseter 
in AM 
Mean value for masseter 
in controls  
Mean value for 
brachiocephalicus in AM 
Mean value for 
brachiocephalicus in 
controls 
Mean value for triceps in 
AM 
Mean value for 
iliospinalis in AM 
Mean value for 
iliospinalis in controls 
Mean value for 
quadriceps in AM 
Mean value for 
quadriceps in controls 
Mean value for 
semitendinosus in AM 
Mean value for 
semitendinosus in 
controls 
Mean value for 
intercostales in AM 
Mean value for in 
sacrocaud dorsalis in 
controls  
Mean value for 








































































































































































































































































































































































































































































































































































































































































































































































3. HIGH RESOLUTION RESPIROMETRY 
From 0.6 to 4.1 mg wet weights of sample obtained by micro-biopsy were used per chamber of the 
oxygraph. The two muscle samples of the AM affected horse (AMa and AMb) showed a severely 
diminished mitochondrial respiration compared to those of the control horses. In all steps of the titration 
protocol, they showed a much lower O2 flux. The most important increase in mitochondrial respiration in 
the AM affected horse was encountered when succinate was added as a substrate (respiratory stimulation 
by convergent electron flow from Complexes I+II following addition of Complex I+II substrates; Figures 
20a,b and 21a,b, 22; Table XVI). 
Little differences were noted between the two different samples of the affected horse (AMa and 
AMb). However, the respiratory capacity in the active coupled state (i.e. coupled OXPHOS capacity with 
Complex I substrates; see Table II) was slightly increased in AMb vs. AMa. Nevertheless, the oxygen flux 
remained largely below the minimum flux found in control horses following addition of Complex I 
substrates in presence of ADP (i.e. 7.9 vs. 23.7 pmol·s-1·mg-1). When the ETS was uncoupled from the 
OXPHOS, the respiration increased in AMa as in all control horses, showing a limiting factor by the 
OXPHOS. In contrast to AMa, AMb did not increase its respiration during uncoupling (Figure 22 and 
Table XVI). 
In the control horses and the AM affected horses, stimulation of respiration by adding ADP in the 
medium showed coupling (i.e. OXPHOS is functional), whereas the absence of the cytochrome c effect 
shows intactness of the outer membrane (Figure 22 and Table XVI). 
 
Figure 20a - Respiration of permeabilized muscle fibers sampled from atypical myopathy 














































GM GM-D GM-Dc GMS-Dc GMS-UC S/Rot AA
O2 ADP CytC Succ FCCP1µl Rot AAGM+Sample  
 
Legend: Oxygen concentration ([µM] blue line) and oxygen flux per mg wet weight of muscle 
([pmol·s-1·mg-1] red line) in permeabilized fibers from atypical myopathy affected horse skeletal 
muscle with the standard titration protocol (see Table II).  Events are labelled in green. 
 
 
Figure 20b – Oxygen flux at steady state during the different steps of the respiration study 





















Legend: See Table II for explanation of the abbreviations. 
















































GM GM-D GM-Dc GMS-Dc GMS-UC S/Rot AA
ADP CytC Succ FCCP Rot AAGM+Sample  
 
Legend: Oxygen concentration ([µM] blue line) and oxygen flux per mg wet weight of muscle 
([pmol·s-1·mg-1] red line) in permeabilized fibers from control horse skeletal muscle with the 
standard titration protocol (see Table II).  Events are labelled in green. 
 
 
Figure 21b – Oxygen flux at steady state during the different steps of the respiration study 






















Legend: See Table II for explanation of the abbreviations. 















Legend: AMa, AMb: atypical myopathy affected horse sampled at 3 and at 10 days, respectively, 




Table XVI - Comparison of the oxygen flux per mg wet weight of muscle (pmol·s-1·mg-1) 
between the horses 
 
GM GM-D GM-Dc GMS-Dc 
GMS-
UC S/Rot AA 
Control horses 
Mean 6.8 39.9 41.1 79.4 91.8 57.7 1.9 
SD 2.6 15.3 16.2 26.1 30.1 18.6 1.5 
Minimum 3 23.7 22.1 44.8 65.8 36.9 -0.2 
Maximum 10.8 76.2 81.2 143.4 164.9 98.3 3.7 
Atypical myopathy affected horse 
AMa 7.3 12.7 11.9 29.1 44.1 23 -0.7 
AMb 0.6 7.9 8.3 37.1 38.3 31.5 1.6 
Ratios versus controls 
AMa  32% 29% 37% 48% 40%  
AMb   20% 20% 47% 42% 55%  
 
Legend: AMa, AMb: atypical myopathy affected horse sampled at 3 and at 10 days, respectively, 




Most results of this epidemiological study on European cases were in accordance with previous 
studies (Votion et al., 2007b; Votion et al., 2008) on confirmed Belgium cases. However, some important 
differences have been remarked. Firstly, the outbreaks during this study period were less devastating than 
previously reported outbreaks (Puyalto-Moussu et al., 2004; Votion et al., 2004) with a larger number of 
survivors (the overall survival rate during the studied period was 28% vs 15% (Puyalto-Moussu et al., 
2004; Votion et al., 2004)). This study also describes fewer horses found dead before showing clinical 
signs (0% vs 5%), fewer recumbent horses (64% vs 96%) and a longer survival time (until 10 days vs 3-72 
H) than in previous reports (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 
2007b). These differences might be explained by a less severe affection of horses during the study period 
compared to other years, and/or by geographic differences. Indeed, geographic differences concerning 
survival rate were revealed, demonstrated by the high survival rate in France during the autumn of 2006. 
They might be explained by different pasture characteristics and management between countries. 
Secondly, also demographic differences have been remarked. In the past, mostly young horses 
were reported to be affected by AM (Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; 
Palencia and Rivero, 2007; Votion et al., 2007b; Votion et al., 2008), but the current study population 
consisted of as well young as old horses and no risk factor for young horses was demonstrated in this 
study. In a previous study (Votion et al., 2008), age was presumed to be a confounding factor for the 
increased risk for stallions, but in the current study without the presence of an age predisposition the sex 
predisposition still remains visible; stallions were more and mares less at risk for the development of the 
condition. Poor or normal body condition could neither be confirmed as a risk factor for the development 
of AM as previously described (Votion et al., 2007b; Votion et al., 2008), however obesity was found to 
be a positive prognostic factor on the outcome. Some affected horses were extremely muscular. This 
parameter was not established on every case, but some horses seen at Liege University were in very good 
body condition and were extremely muscular considering their age. The present study described for the 
first time clinically affected donkeys and zebra’s. To date, no proof has been provided for AM affecting 
other species than equidae although a deer was present in the LP group. Equidae are known to be more 
susceptible for certain toxins (i.e. mycotoxins and clostridial toxins) than other species (Green et al., 1994; 
Osweiler, 2001; Renninger and Hooser, 2003). 
New clinical aspects of AM have been demonstrated by studying the HP/CC group: hyperthermia 
was more often present than in previous studies (Votion et al., 2007b), quite some cases showed a delayed 
transit (mucus covered faeces, colon impaction) and some males showed a penile prolapse. The presence 
of stiffness and high CK activities were important clinical parameters to differentiate between AM from 
conditions resembling AM.  Since the first measured CK activities in AM affected horsed were not always 
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that much increased, it is recommended in case of low CK activity at the beginning of the clinical signs to 
repeat the analysis 24H later. In literature, one horse had been described to be stabled for a day when the 
first clinical signs of AM were noted (Votion et al., 2007b). The present study showed two horses being 
stabled for 2 days before showing clinical signs. Thus it can be suggested that the causative agent needs 
several days to exert its action. Moreover, this study confirmed that horses need to be on the specific 
pasture for at least one week to be affected by AM (Votion et al., 2007b). 
Also some differences concerning management of horses and their pastures and pasture 
characteristics were revealed: the presence of trees was identified as a new risk factor, and several 
previously determined risk or protective factors were not confirmed by this study (no risk factor: the 
presence of a slope on pasture; no protective factor: regular vaccination and deworming). Unfortunately, 
for several other parameters the statistical analysis was impossible due to the poor amount of answers. 
This is the first study describing survivors of AM. Unexpectedly, they recover uneventful and 
show surprisingly little muscle wastage regarding the severity of the myopathy. Knowing that AM 
affected horses have a chance to survive without apparent sequellae is of great importance for equine 
practitioners with respect to diagnosis, prognosis and treatment. Previously, normal respiration with 
normal PaO2 levels had been identified as a possible positive prognostic factor, although on fatal cases 
(Votion et al., 2007b). In most described cases of the current study PaO2 levels were not measured and 
normal respiration could not be confirmed as positive prognostic factor due to a lack of answers. 
Nevertheless, normal mucosae, remaining standing for most of the time and obesity were identified as 
positive prognostic factors, whereas recumbency was a negative prognostic factor. Serum activities of CK 
had a tendency to be higher in survivors than in non-survivors, confirming previous observations that CK 
is not a liable prognostic indicator (Votion et al., 2007b). Differences between survivors and non-
survivors concerning pasture characteristics and management can be interpreted as risk or protective 
factors. Indeed, an interesting difference between pastures was marked: pastures of survivors contained 
more dead wood than those of non-survivors. Dead wood was described in other reports to be frequently 
present on pastures where AM cases declare (Votion et al., 2007b; Votion et al., 2008), suggesting that it 
is of direct or indirect importance for the causative agent. It might be possible that survivors had been 
more in contact with the causative agent due to the presence of dead wood and have developed certain 
immunity. 
Previous studies on affected cases have suggested a dysfunction in mitochondrial lipid 
metabolism (Cassart et al., 2007; Votion et al., 2007b; Westermann et al., 2007; Westermann et al., 
2008b). In human medicine, several inborn disorders in mitochondrial lipid metabolism are described 
(Nyhan, 2005). Clinically, they present with myopathies and cardiomyopathies, and sometimes liver 
involvement is noticed (Nyhan, 2005). They can originate from the different steps in the carnitine transfer, 
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or from fatty acid β oxidation. During the β oxidation two enzymes may be deficient: acyl-CoA 
dehydrogenases and HAD. Problems can also occur when the electrons produced during the β oxidation 
enter the ETS with ETF and ETF:QO or when the produced acetyl-CoA enters the Krebs cycle (Nyhan, 
2005). In any condition in which FFA accumulate, esterifications with carnitine and accumulation of acyl-
carnitines takes place (Nyhan, 2005). Inborn errors cause not necessarily clinical problems in newborns 
and may only lead to the development of clinical signs later on in life (Nyhan, 2005).  Since AM occurs 
only in pasturing horses of all breeds (Votion et al., 2004; Votion et al., 2007b; Votion et al., 2008) and 
seen its seasonal character (Hosie et al., 1986; Whitwell et al., 1988; Palencia and Rivero, 2007; Votion et 
al., 2007b), the metabolic problem in AM would probably not concern an inborn error, but an acquired 
one. 
Indeed, the present study demonstrated a severe problem in fatty acid metabolism. A smaller 
amount of triglycerides and a larger amount of monoglycerides were visualised at the TLC in affected 
muscles compared to control muscles. Triglycerides consist of FFA bound to glycerol and limited amounts 
are stored in muscle cells as energy source (Lehninger et al., 1993d; MacLeay, 2004). Seen the important 
energy deficit in affected horses (as suggested by the accumulation of AMP metabolites in urine and 
muscle glycogen depletion (Westermann et al., 2008a)), the stored triglycerides probably were degraded 
into FFA and glycerol with monoglycerides as intermediates. Also a severe increase in muscular FFA was 
found in the affected group. In normal muscle cells a small amount of FFA is stored (Nawrocki et al., 
1999). In AM affected horses, the important increase in sarcoplasmatic FFA probably is derived from 
degraded intracellular stored triglycerides, maybe even from catabolism of structural lipids (phospholipids 
of membranes), and most certainly from the FFA liberated in the bloodstream by adipocytes secondary to 
the energy demand.  The latter corresponds to the frequently encountered hyperlipaemia (Delguste et al., 
2002; Votion et al., 2004; Votion et al., 2007b). Since the FFA cannot be metabolised further, they 
accumulate in the sarcoplasm, giving rise to dramatic amounts of lipid droplets visualised on histology by 
Oil red O staining (Cassart et al., 2007). Strangely enough, no difference was present in the amount of 
total muscular lipids between the groups. The increase in FFA (in µg/gram muscle) was too small to make 
a difference on total lipids (in mg/gram muscle). Nevertheless, still important lipid accumulations are 
visible on histology in affected horses in contrast to normal horses. The affinity for neutral lipids (FFA 
and their derivatives) and the poor coloration of structural fats and fats of other classes of the Oil red O 
staining (Bayliss High and Lake, 1990) and a possible increase in FFA from catabolism of structural lipids 
might account for this phenomenon. It would be interesting to perform specific histological stainings for 
different lipid classes on future muscle samples of affected horses to confirm this hypothesis. 
The present study shows no significant changes between the FFA profiles of the chromatograms 
of the different horses. This means that they have the same FFA in their muscles, however occurring in 
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different percentages and quantities. The minor differences in profiles between the horses can probably be 
explained by different feeding practices as the composition of accumulated lipids in skeletal muscle has 
been reported to be highly reflective of dietary fat (Andersson et al., 2002; Perez-Palacios et al., 2007). In 
human beings however, it is rare to find long chain FFA longer than 20 carbons (Kotani et al., 2000). 
Their presence in all of the studied horses might be a species specific finding. 
However, important differences have been noted in quantities of FFA, where AM affected 
muscles contained more FFA than control muscles. In controls, palmitic acid (C16:0) was almost always 
the most abundant FFA. Palmitic acid is the precursor of other long-chain FFA (Lehninger et al., 1993c) 
and has been reported to be a major FFA in human plasma (Mehta et al., 1998) and in skeletal muscle 
tissue of rats (Gorski et al., 1998). An explosive increase in palmitoleic acid (C16:1) was demonstrated in 
affected muscles. Palmitoleic acid is also a major FFA in human plasma (Mehta et al., 1998) and is the 
desaturated version of palmitic acid, containing a double bond between C9 and C10. Palmitoleic acid has 
been reported to increase in human plasma with dyslipaemia (Zak et al., 2000) and in plasma, liver and 
muscle tissue of obese rats (Fukuchi et al., 2004). Besides these relations with pathologies of lipid 
metabolism, changes in muscular FFA content and composition of blood FFA correlate with insulin 
resistance and impaired glucose disposal in skeletal muscle. However, contradictory results with respect to 
the effects of palmitoleic acid on insulin action have been reported; it may promote insulin resistance 
(Fukuchi et al., 2004), or enhance insulin-stimulated glucose transport (Dimopoulos et al., 2006). 
Interestingly, impaired insulin sensitivity influenced FFA desaturase activity (Vessby et al., 2002). In AM, 
pathological metabolic situations like hyperlipaemia, hyperglycaemia and a suspicion of insulin resistance 
are present (Delguste et al., 2002; Votion et al., 2004; Votion et al., 2007b). Thus the increase of 
palmitoleic acid is in accordance with observations in human beings and rats, although they reflect more 
chronic processes. Nevertheless, a significant increase of FFA has been already observed after 7 hours 
fasting, showing the possibility of fast occurring changes in plasmatic FFA (Kotani et al., 2000). 
The muscles with the highest amount of FFA, as well in affected as control horses, are all muscles 
known to have a high amount of fiber type I (M. masseter, Mm. intercostales and myocardium). 
Interestingly, the M. masseter showed the lowest increase in muscular FFA when comparing control 
horses to affected horses. In rats, the same phenomenon has been observed secondary to a pathological 
increase in plasma glucose: more important amounts of FFA in muscles with a high proportion of type I 
fibers, but a less important increase of FFA by these muscles (Nawrocki et al., 1999). These type I fibers 
depend largely on aerobic metabolism of glucose and fatty acids for their energy (MacLeay, 2004). As 
mentioned in the introduction, AM affects mostly type I fibers, being respiratory and postural muscles 
(Brandt et al., 1997; Cassart et al., 2007; Palencia and Rivero, 2007). 
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Recently, the metabolic defect occurring in AM was defined as MADD based on characteristic 
profiles of organic acids and acyl-carnitines in urine, plasma and muscle tissue, and the finding of 
deficiencies of short and medium chain acyl-CoA dehydrogenases and isovaleryl dehydrogenase 
(Westermann et al., 2007; Westermann et al., 2008b). The acyl-carnitines measured in these studies are 
acyl-fatty acid chains bound to carnitine that already partially have been cut in smaller chains in the 
mitochondria. In a normal functioning β oxidation the chains are cut in portions of 2 carbons. Due to the 
deficiency they are cut in larger pieces, resulting in an increased amount of short and medium chain acyl-
carnitines. The deficient cutting explains the presence of uneven acyl-carnitine chains, usually not present 
in mammals, and the binding of carnitine with short chain fatty acids (FFA smaller than 12 carbons can 
enter the mitochondria freely (Lehninger et al., 1993e)). The latter studies looked at fatty acid metabolism 
by a very different approach than the present study, where all muscular FFA have been measured.  The 
chloroform, used to dissolve the lipids in the present study, breaks connections between lipids and 
proteins, thus including the acyl-fatty acids chains, which are now deconnected from carnitine, in the 
measured muscular FFA. Due to the different approach between these studies, not the same lipid classes 
were studied and thus not the same lengths of fatty acid chains were increased. 
Additional metabolic deficiencies described about AM are: increased uric acid excretion in urine 
due to degradation of AMP (demonstrating ATP depletion), glycogen depletion, increase of glycolytic 
enzymes except a very low activity of the enzyme phosphoglycerate mutase (PGAM) in one horse 
(Westermann et al., 2008a). The amount of mitochondria was not changed (concluded by a normal 
amount of citrate synthase) (Westermann et al., 2008a), although the overall oxidative potential of 
myofibers was weaker as demonstrated by NADH tetrazolium reductase (NADH-TR) (Cassart et al., 
2007) and the histochemical assay for succinate dehydrogenase (SDH) (Palencia and Rivero, 2007). 
Moreover, with electronic microscopy also ultrastructural changes of the mitochondria have been 
visualised (Cassart et al., 2007).  Results of the histochemical staining with NADH-TR are related to the 
mitochondrial respiratory Complex I and/or mitochondrial alterations, whereas weak staining with SDH 
suggests biochemical defects associated with the mitochondrial respiratory Complex II and/or 
mitochondrial alterations. 
With HRR, a severely diminished activity of the mitochondrial respiration of the affected horse 
was found in every titration step. This means that Complex I and Complex II showed lowered activity, 
although Complex I seemed more severely affected than Complex II. On the contrary, in a previous report, 
the activity of Complex II was reported to be the most decreased (59% of control horses) compared to the 
activities of the other complexes (75% of control horses) (Westermann et al., 2008a). However, the 
spectophotometric methods used to measure the activity of the complexes assess activity of individual 
complexes rather than in an integrated manner like HRR does. 
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Westermann and collaborators (2007, 2008b) hypothesised a FAD-dependent dysfunction seen the 
decreased activity of several dehydrogenases, which all utilized FAD as cofactor (including acyl-CoA 
dehydrogenases and isovaleryl dehydrogenase).  In this hypothesis, the diminished activity of Complex II 
would result from a dysfunction of its FAD prosthetic group (electrons move from succinate to FAD, then 
to coenzyme Q which passes electrons to Complex III).  Such FAD-dependent dysfunction might result 
from a riboflavin deficiency. Riboflavin, also known as vitamin B2, is a precursor in the synthesis of FAD 
and flavin mononucleotide (FMN), another flavin nucleotide, both required as coenzymes by 
flavoproteins.  No riboflavin deficiency was present in AM affected horses, but the possibility of a 
competition between riboflavin and a toxin can not be ruled out (Westermann et al., 2008b). However, not 
all FAD-dependant enzymes are deficient in AM; the activities of ETF and the ETF:QO were measured to 
be normal (Westermann et al., 2007). Moreover, the switch of palmitic acid to its desaturated form 
palmitoleic acid demonstrated by the present study suggests that FFA desaturases, which are also FAD 
dependant (Lehninger et al., 1993c), function correctly.  It is worth noting that Complex I itself is a 
flavoprotein, but which uses FMN rather than FAD as cofactor.  Several flavoproteins are even known to 
impair electron transfer in the ETS, some of them demonstrating a stronger inhibition activity for 
Complex I than Complex II (Hodnick et al., 1994).  Further researches should explore the presence of 
these compounds in samples collected on AM cases and/or in their environment. 
In time, small alterations were visible in the affected horse. AMb showed an increase in O2 flux 
by Complex II, whilst no change was found in Complex I compared to AMa. This means that at 10 days 
after the first signs of AM were noticed, the horse started to regain some, although minor, activity of 
Complex II, while at a clinical point of view he had severely deteriorated. In the future, HRR can 
potentially be used as a clinical guide for decision making in AM, since ameliorations in mitochondrial 
respiration measured by HRR will sooner be visible than clinical improvement. The time between 
muscular sampling and obtaining results is reasonable for clinical decision making. Despite, it cannot be 
excluded that even when the mitochondrial respiration ameliorates, negative secondary effects continue to 
cause damage possibly leading to the death of the horse. Further research with a follow up in time of 
several cases affected with AM should test this hypothesis. Survivors of AM have been described in the 
epidemiological part of the study and recovery was noted after 2 to 30 days (mean 11.1 ± 6.9 days) since 
the onset of clinical signs. It can be postulated that survival occurs when the action of the etiological cause 
of AM has elapsed, is destroyed or inactivated, or when its pathological effects has been bypassed by the 
body. This acute, severe myopathy resembles certain clostridial toxin and/or mycotoxin induced diseases, 
where also a certain time span is needed to overcome the effects of the toxin and where recovery can be 
uneventful as well (Osweiler, 2001; Renninger and Hooser, 2003; Van Galen et al., 2008a). 
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With the present epidemiological and pathophysiological study, some new aspects concerning 
treatment and prevention can be proposed. Treatment has already been set out in the introduction and only 
new aspects will be discussed. Seen the severe defects in mitochondrial lipid metabolism occurring in AM 
affected horses, but not in carbohydrate metabolism, it might be beneficial to enhance carbohydrate 
metabolism by supplementing carbohydrates and stimulating insulin sensitivity. Carbohydrate 
supplementation can be performed by adapting nutrition or by glucose administration.  Most horses keep a 
good appetite; some of them are even craving for food (Votion et al., 2007b). In those cases, a reduced 
quantity of fat and a high quantity of carbohydrates (for example concentrates with molasses, grains, corn, 
fruits, honey, sugar water, sugar blocks, fresh grass) might be beneficial.  Small amounts of food 
frequently over the day should prevent peaks in hyper- and/or hypoglycaemia and fasting should be 
avoided at all times. Exaggeration, however, should not be encouraged since carbohydrate overload can 
cause deleterious effects (endotoxaemia, gas distension, diarrhoea, laminitis). Especially horses not used 
to digest large amounts of carbohydrates are at risk for these complications (Jones, 2004).  Increasing 
carbohydrate content is contradictory to nutritional advice for several other equine myopathies, proposing 
a decrease of carbohydrates and an increase of lipid content (MacLeay, 2004).  If horses are not eating 
well, or when hyperlipaemia and hyperglycaemia maintain, glucose can be administrated orally or 
intravenously (Barton, 2004).  At the same time, glucose also supports the affected hepatic metabolism 
(Hosie et al., 1986; Whitwell et al., 1988; Brandt et al., 1997; Votion et al., 2004) by decreasing the need 
for hepatic gluconeogenesis (Barton, 2004). Seen the hyperglycaemia (Hosie et al., 1986; Whitwell et al., 
1988; Brandt et al., 1997; Votion et al., 2007b), the diminished or depleted intrasarcoplasmatic glycogen 
stores (Westermann et al., 2008a), the increased activity of carbohydrate metabolism (Westermann et al., 
2008a) and the energetic dysbalance, a certain degree of insulin resistance is suspected to occur in AM-
affected horses.  To stimulate insulin sensitivity and thus the glucose uptake in skeletal muscle, insulin can 
be administrated under regular control of the serum glucose levels (Bertone and Horspool, 2004).  Several 
human products, as chromium (III) or metformin, have been described to enhance insulin sensitivity, but 
conflicting results of efficacy are reported in horses (Firshman and Valberg, 2007; Anderson, 2008). On 
the contrary, corticosteroids and alpha2-agonists induce insulin resistance (Firshman and Valberg, 2007) 
and thus should be avoided.  Heparin can be administrated to further control the hyperlipaemia by 
potentiating lipoprotein lipase activity (Barton, 2004).  This might increase triglyceride removal from the 
blood back into adipose tissue, but probably lipoprotein lipase is already at maximum rate, as is the case in 
hyperlipaemic poneys, and additional benefit of heparin can be questioned (Barton, 2004). 
Following the hypothesis of MADD due to a riboflavin blockage, a supplementation of affected 
horses with this vitamin B2 (via B-complex vitamin supplementation) might be usefull (Westermann et 
al., 2007; Westermann et al., 2008b). The daily requirements of a healthy mature horse for riboflavin are 
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12 mg, and good-quality hay, alfalfa or pasture normally contain largely enough (Rooney, 2004). 
Dependant on the severity of AM, the requirements of riboflavin in affected horses probably exceed those 
for healthy horses. 
Special attention should be given to the digestive system as several horses with colic signs and 
diminished transit were reported in this study and recently by Sherlock and Mair (2008) (Sherlock and 
Mair, 2008). Passage of electrolytes and paraffin per nasogastric tube and offering good quality of fibers 
might avoid further problems. 
Some preventive methods have been highlighted by this study. Seen that horses can be affected by 
the condition until two days being stabled, one can estimate horses being save from the condition once 
they have been stabled for at least 3 days. When not enough boxes are available to stable all horses during 
an outbreak, it is advised to give priority to not working horses, young and older horses and to stallions. 
Complementation of horses with food during the risk periods of AM decreases the risk at AM. 
This study has several limitations. Since also non-confirmed or non-infirmed cases were included 
in the epidemiological study and since the files of the studied cases were not always complete, 
categorizing the horses was sometimes difficult. Probably, some horses were AM affected, but did not end 
up in the CC or HP category due to lacking information. The reverse is also possible: cases not being AM 
affected, but nevertheless entering the HP group because of the presence of a myopathy induced by 
another cause. A second limitation is the underestimation of the real number of European cases. One 
explication for this underestimation is the rapid death of AM cases (Hosie et al., 1986; Whitwell et al., 
1988; Brandt et al., 1997; Votion et al., 2007b), which complicates establishing a clinical diagnosis. 
Another important reason for the underestimation of the disease is that not every AM affected case has 
been communicated. Co-grazing horses can be subclinically affected and are per definition grazing on the 
same premises as affected horses, which makes them less ideal objects for a control group regarding 
pasture characteristics and management, but more ideal concerning demographic data. To demonstrate 
other differences between groups and with more certainty, a larger study population is required. Especially 
for the HRR other cases should be used to confirm the findings of this study. 
In conclusion, the epidemiological part of this study demonstrates a less devastating outbreak than 
previously reported, together with some new clinical presentations of the condition. The 
pathophysiological part confirmed the severe mitochondrial dysfunctions in the β oxidation of the FFA 
and in Complex I and II of the ETS. Further research is necessary to find the cause of AM and to better 
understand its pathophysiology in order to establish an effective treatment and prevention. 
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